New drug PG-033 enters first human safety tests

NCT ID NCT07013097

Recruiting now Knowledge-focused Sponsor: Prime Gene Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the safety of a new drug called PG-033 in 52 healthy adults aged 18 to 45. Participants receive either a single dose of PG-033 or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if a high-fat meal changes drug absorption. No treatment benefit is expected; the goal is to gather safety information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LICHEN SIMPLEX CHRONICUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurodermatitis Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LICHEN SIMPLEX CHRONICUS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Shijitan Hospital , Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100038, China

Contact Phone: •••-•••-•••• Email: •••••@•••••